Table 1.
All Subjects | MSS | MSI - H/Hypermutated | POLE | |
---|---|---|---|---|
Total patients | 1099 | 995 (90.5%) | 96 (8.7%) | 8 (0.7%) |
Age (years) | ||||
Mean +/− SD | 54.5 ± 12.8 | 54.2 ± 12.4 | 57.6 ± 16.5 | 51.0 ± 13.7 |
Median | 54 | 54 | 60.5 | 52 |
Range | 13–93 | 13–93 | 20–85 | 24–70 |
Sex | ||||
Male | 597 (54.3%) | 536 (53.9%) | 54 (56.3%) | 7 (87.5%) |
Female | 502 (45.7%) | 459 (46.1%) | 42 (43.8%) | 1 (12.5%) |
Stage at diagnosis | ||||
Stage I | 40 (3.6%) | 34 (3.4%) | 6 (6.3%) | 0 (0%) |
Stage II | 128 (11.6%) | 88 (8.8%) | 37 (38.5%) | 3 (37.5%) |
Stage III | 267 (24.3%) | 228 (22.9%) | 35 (36.5%) | 4 (50%) |
Stage IV | 664 (60.4%) | 645 (64.8%) | 18 (18.8%) | 1 (12.5%) |
Primary tumor site | ||||
Right colon | 326 (29.7%) | 254 (25.5%) | 67 (69.8%) | 5 (62.5%) |
Left colon | 505 (45.9%) | 482 (48.4%) | 20 (20.8%) | 2 (25%) |
Rectum | 255 (23.2%) | 246 (24.7%) | 8 (8.3%) | 1 (12.5%) |
NOS | 14 (1.3%) | 13 (1.3%) | 1 (1%) | 0 (0%) |
Race | ||||
White | 866 (78.8%) | 784 (78.8%) | 78 (81.3%) | 4 (55.6%) |
Black | 74 (6.7%) | 68 (6.8%) | 5 (5.2%) | 1 (11.1%) |
Asian | 74 (6.7%) | 67 (6.7%) | 5 (5.2%) | 2 (22.2%) |
Native Hawaiian | 1 (0.1%) | 1 (0.1%) | 0 (0%) | 0 (0%) |
Other | 7 (0.6%) | 7 (0.7%) | 0 (0%) | 0 (0%) |
Unknown | 77 (7.0%) | 68 (6.8%) | 8 (8.3%) | 1 (11.1%) |
Sample Histology | ||||
Conventional | 572 (50.4%) | 546 (53.2%) | 24 (24.2%) | 2 (25%) |
Conventional with mucinous component | 88 (7.8%) | 67 (6.5%) | 19 (19.2%) | 2 (25%) |
MANEC | 3 (0.3%) | 2 (0.2%) | 1 (1%) | 0 (0%) |
Medullary | 2 (0.2%) | 0 (0%) | 2 (2%) | 0 (0%) |
Mucinous | 33 (2.9%) | 23 (2.2%) | 9 (9%) | 1 (12.5%) |
PDC | 82 (7.2%) | 67 (6.5%) | 14 (14.1%) | 1 (12.5%) |
Signet ring cell | 5 (0.4%) | 5 (0.5%) | 0 (0%) | 0 (0%) |
N/A and Other | 349 (30.8%) | 317 (30.9%) | 30 (30.3%) | 2 (25%) |
Sample Grade | ||||
Moderately differentiated | 595 (52.5%) | 555 (54.0%) | 36 (36.4%) | 4 (50%) |
Moderately to poorly differentiated | 92 (8.1%) | 78 (7.6%) | 13 (13.1%) | 1 (12.5%) |
Poorly differentiated | 96 (8.5%) | 77 (7.5%) | 18 (18.2%) | 1 (12.5%) |
N/A and Other | 351 (31.0%) | 317 (30.9%) | 32 (32.3%) | 2 (25%) |
Sample Type Sequenced | ||||
Total samples | 1134 | 1027 (90.6%) | 99 (8.7%) | 8 (0.7%) |
Early Stage Primary | 123 (10.8%) | 61 (5.9%) | 59 (59.6%) | 3 (37.5%) |
mCRC Primary | 478 (42.2%) | 447 (43.5%) | 28 (28.2%) | 3 (37.5%) |
mCRC Metastasis | 53435 (47.0%) | 519 (50.5%) | 12 (12.1%) | 2 (25%) |